Current status of and barriers to the treatment of advanced-stage liver cancer in China: a questionnaire-based study from the perspective of doctors

Abstract

Background Liver cancer is a severe public health problem worldwide, and it creates a relatively higher disease burden in China than in the Western world. Despite achieving notable progress in China, potential differences in some aspects of medical services for liver cancer may persist across different regions and hospitals. This warrants serious consideration of the actual status of and barriers to liver cancer treatment. We intended to explore the present status of and obstacles in liver cancer treatment especially for advanced-stage liver cancer. Methods In February 2021, a national multicenter cross-sectional study was conducted among 1500 doctors from 31 provinces of mainland China using a self-administered online questionnaire. Participants completed the questionnaire about their general information, perspectives on the current status of liver cancer treatment, and expectations for future treatment. Chi-square and logistic regression analyses were performed to explore the differences associated with the regions, doctors’ professional ranks, and hospital levels. Results Treatment conditions, medications, and treatment strategies were inconsistent across different economic regions and hospital of different levels. With respect to obstacles in treatment, 76.6% of the doctors were unsatisfied with the current treatment for liver cancer. Important factors that influenced their satisfaction with the treatment for liver cancer included early diagnosis and the disclosure of true conditions to patients. Conclusions There persists differences in the treatment of liver cancer in China, besides barriers to treatment. More attention should be paid to the detection and treatment of liver cancer and the propagation of novel progress among doctors in underdeveloped areas.

What are the changes in the hotspots and frontiers of microRNAs in hepatocellular carcinoma over the past decade?

“…As the understanding of the carcinogenic factors that cause liver cancer has improved worldwide, researchers have developed new treatment strategies, such as immunotherapy and targeted therapies. The continuous development of new technologies and drugs provides hope for further diagnosis and treatment of liver cancer[ 3 ]. Hepatocellular carcinoma (HCC) accounts for 85%-90% of primary liver cancers and is highly drug-resistant, making it difficult to treat.…”

Benefits of a modified local precision liver resection using intraoperative laparoscopic ultrasound in the treatment and prognosis of patients with liver cancer.

“…Liver cancer is a malignant tumor that seriously affects Chinese residents' health, and its incidence is relatively high 1,2 . The early stage of hepatocellular carcinoma courses with insidious characteristics and rapid growth, but it is often diagnosed in the middle and late stages.…”